Effect of Unani Drug on increased Serum Uric acid.

Efficacy of Zarawand in Hyperuricemia: A Randomized Standard Controlled Study.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/024001

Enrollment

Registered

2020-03-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E799- Disorder of purine and pyrimidinemetabolism, unspecified

Interventions

Intervention1: Zarawand: Zarawand (4gm) will be given in capsule form in 2 divided doses

each capsule will contain 1gm of the Zarawand, for 4 weeks daily Control Intervention1: Febuxostat: Febuxostat 40 mg will be given once a day.

Eligibility

Inclusion criteria

Inclusion criteria: Patients Uric acid >6 mg/dl eGFR >90ml/min/1.73m2

Exclusion criteria

Exclusion criteria: Pregnant and lactating mothers Diabetes Mellitus, Poorly controlled hypertension Blood pressure >=160/100 Significant liver or Renal dysfunction cardiovascular diseases A Medical condition that in the investigators opinion would interfere with the treatment, safety, or adherence to the protocol

Design outcomes

Primary

Measure	Time frame
Reduction in Serum uric acidTimepoint: 0th and 28th day	—

Secondary

Measure	Time frame
Improvement in subjective parametersTimepoint: 0th and 28th day	—

Countries

India

Contacts

Public ContactDr Muzafar Din Ahmad Bhat

NATIONAL INSTITUTE OF UNANI MEDICINE

drmuzaffar79@gmail.com9590366192

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026